Upcoming Programs Registration
Save the Dates!
Fall Date: Friday 4 November 2022
Spring Date: Friday 31 March 2023
Times: 7:00 AM – 5:00 PM PDT
Location: Seattle Convention Center
Address: 705 Pike Street, Seattle, WA 98101-2310
Rooms: 606-609 & 611-614
Virtual Option: All registrants will also gain access to post-conference recordings provided as Enduring Materials. Details to come.
Upcoming Events
Fri, Mar 31Seattle Convention CenterMar 31, 2023, 7:30 AM – 5:00 PM PDTSeattle Convention Center, 705 Pike St, Seattle, WA 98101, USAThis upcoming Spring 2023 conference is planned for a return to the Seattle Convention Center. We look forward to having you join us for learning and networking. Post-conference enduring material option is being strategized, if viable. We are planning a half day Diabetes, and half day Adrenal.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Washington State Medical Association (WSMA) and the Endocrine Days Educational Institute. The WSMA is accredited by the ACCME to provide continuing medical education for physicians.
The WSMA designates this Live activity for a maximum of 7.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the criteria for up to 7.25 hour(s) of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
Planners: The following planners have indicated (a) relevant financial relationship(s) with an ACCME-defined ineligible company:
Savitha Subramanian, Abbott Diabetes Care, advisory board member; Akcea Therapeutics, advisory board member; Amarin, advisory board member. Kristina Utzschneider, Clinical Care Options, speaker; Endocrine Society, speaker; Nevro, consultant.
All relevant financial relationships have been mitigated. All others in control of content have indicated no relevant financial relationship with an ACCME-defined ineligible company. All clinical content presented will be evidence-based and unbiased.
Faculty: The following faculty have indicated (a) relevant financial relationship(s) with an ACCME-defined ineligible company:
John K. Amory, Clarus Therapeutics, board member; Ferring, contracted research. Matt Kaeberlein, Optispan Geroscience, LLC, Founder, and CSO; Ora Biomedical, Founder and Board of Directors; Loyal, Science Advisory Board (SAB) member; NeuroAge Therapeutics, SAB member; LongeVC, SAB member; HumanEdge, SAB member; Epiterna, SAB member; Noom, Technical Advisor.
All relevant financial relationships have been mitigated. All others in control of content have indicated no relevant financial relationship with an ACCME-defined ineligible company. All clinical content presented will be evidence-based and unbiased.